Cancer Treatment Today

Lynparza is approved for first line BRCA mutated advanced ovarian cancer, mentenance of recurrent ovarian cacner,dvanced gBRCA-Mutated Ovarian Cancer After 3 Or More Lines Of Chemotherapy, Germline BRCA-Mutated HER2-Negative Metastatic Breast Cancer.

There are studies that show conflicting results of effectiveness in gastric cancer. GOLD study,1 compared olaparib plus paclitaxel with placebo plus paclitaxel as second-line therapy for patients with advanced gastric cancer in a double-blind, randomised phase 3 setting.It was a negative study. Another study, A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy, is showing more positive results, but they have not been published to my knowledge.

Bang Y-J Xu R-H Chin K et al.
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017; 18: 1637-1651

Bang Y-J Im SA Lee KW et al.
Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer.
J Clin Oncol. 2015; 33: 3858-3865

Hodgson DR Lai Z Dougherty BA et al.
Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC).
Proc Am Soc Clin Oncol. 2016; 34: 4041